SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 233 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,163 | -14.6% | 477,380 | -6.9% | 0.00% | 0.0% |
| Q2 2023 | $15,422 | -16.5% | 513,004 | +0.6% | 0.00% | -33.3% |
| Q1 2023 | $18,477 | +1.7% | 509,972 | +0.1% | 0.00% | 0.0% |
| Q4 2022 | $18,169 | -99.9% | 509,353 | +0.3% | 0.00% | 0.0% |
| Q3 2022 | $17,192,000 | +16.8% | 507,863 | -0.2% | 0.00% | +50.0% |
| Q2 2022 | $14,713,000 | -11.8% | 508,748 | -1.4% | 0.00% | 0.0% |
| Q1 2022 | $16,684,000 | +10.7% | 516,227 | -0.1% | 0.00% | +100.0% |
| Q4 2021 | $15,073,000 | +8.2% | 516,921 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $13,928,000 | -25.5% | 522,230 | -14.0% | 0.00% | -50.0% |
| Q2 2021 | $18,702,000 | +17.4% | 607,393 | -0.2% | 0.00% | 0.0% |
| Q1 2021 | $15,927,000 | -0.3% | 608,383 | -4.2% | 0.00% | 0.0% |
| Q4 2020 | $15,976,000 | +10.4% | 634,977 | -8.5% | 0.00% | 0.0% |
| Q3 2020 | $14,465,000 | -12.4% | 694,115 | -0.1% | 0.00% | 0.0% |
| Q2 2020 | $16,505,000 | +33.5% | 694,952 | +1.1% | 0.00% | 0.0% |
| Q1 2020 | $12,365,000 | -33.1% | 687,319 | -11.8% | 0.00% | 0.0% |
| Q4 2019 | $18,485,000 | -11.4% | 779,296 | +2.6% | 0.00% | -33.3% |
| Q3 2019 | $20,874,000 | -18.3% | 759,625 | -1.6% | 0.00% | -25.0% |
| Q2 2019 | $25,538,000 | -5.4% | 771,785 | +0.2% | 0.00% | 0.0% |
| Q1 2019 | $26,985,000 | +5.8% | 770,108 | +0.3% | 0.00% | 0.0% |
| Q4 2018 | $25,499,000 | -34.6% | 767,588 | -0.9% | 0.00% | -33.3% |
| Q3 2018 | $38,987,000 | -14.4% | 774,321 | +1.7% | 0.01% | -14.3% |
| Q2 2018 | $45,561,000 | +41.3% | 761,255 | +8.2% | 0.01% | +40.0% |
| Q1 2018 | $32,233,000 | +14.1% | 703,787 | -0.8% | 0.01% | 0.0% |
| Q4 2017 | $28,262,000 | +5.0% | 709,218 | +5.4% | 0.01% | 0.0% |
| Q3 2017 | $26,907,000 | +0.3% | 672,681 | +8.1% | 0.01% | 0.0% |
| Q2 2017 | $26,822,000 | +46.5% | 622,329 | +6.4% | 0.01% | +66.7% |
| Q1 2017 | $18,306,000 | +131.1% | 584,861 | +86.5% | 0.00% | +50.0% |
| Q4 2016 | $7,920,000 | +1311.8% | 313,645 | +1282.6% | 0.00% | – |
| Q3 2016 | $561,000 | -43.6% | 22,685 | -53.6% | 0.00% | – |
| Q2 2016 | $995,000 | +48.3% | 48,860 | +11.0% | 0.00% | – |
| Q1 2016 | $671,000 | -89.6% | 44,010 | -90.8% | 0.00% | -100.0% |
| Q4 2015 | $6,430,000 | -53.2% | 478,430 | -51.1% | 0.00% | -66.7% |
| Q3 2015 | $13,731,000 | -24.7% | 978,665 | -8.9% | 0.00% | -25.0% |
| Q2 2015 | $18,241,000 | +42.1% | 1,074,249 | +1.2% | 0.00% | +33.3% |
| Q1 2015 | $12,833,000 | +8.7% | 1,061,450 | -25.3% | 0.00% | 0.0% |
| Q4 2014 | $11,801,000 | -42.4% | 1,421,832 | -39.7% | 0.00% | -25.0% |
| Q3 2014 | $20,488,000 | -45.4% | 2,357,650 | -31.2% | 0.00% | -50.0% |
| Q2 2014 | $37,546,000 | +0.3% | 3,428,890 | -18.1% | 0.01% | 0.0% |
| Q1 2014 | $37,428,000 | -43.1% | 4,186,551 | -52.0% | 0.01% | 0.0% |
| Q4 2013 | $65,792,000 | +99.3% | 8,725,600 | +93.7% | 0.01% | 0.0% |
| Q3 2013 | $33,019,000 | -45.8% | 4,504,600 | -52.5% | 0.01% | 0.0% |
| Q2 2013 | $60,952,000 | – | 9,479,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |